Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25098463 | 0.86 | CARM1 (0.34) | CARM1PRMT6ROCK2ROCK1KDM4E | |
| SCHEMBL25786362 | 0.86 | ALDH1A1 (0.37) | CARM1PRMT6KDM4ECCR5 | |
| SCHEMBL18082542 | 0.85 | BCHE (0.42) | CARM1PRMT6ROCK2ROCK1KDM4E | |
| SCHEMBL10076884 | 0.85 | BCHE (0.42) | CARM1PRMT6ROCK2ROCK1KDM4E | |
| SCHEMBL22020562 | 0.83 | CYP3A4 (0.35) | KDM4EDRD2DRD3ACHECHRM5 | |
| SCHEMBL9925435 | 0.83 | CYP3A4 (0.35) | KDM4EDRD2DRD3ACHECHRM5 | |
| SCHEMBL26345081 | 0.83 | PIK3CD (0.41) | CARM1PRMT6KDM4EACHECHRM5 | |
| SCHEMBL7797268 | 0.82 | CHRM5 (0.52) | CARM1PRMT6ROCK2ROCK1KDM4E | |
| SCHEMBL13077 | 0.81 | KDM4E (0.50) | KDM4EHTR7 | |
| SCHEMBL13995508 | 0.81 | KDM4E (0.50) | KDM4EHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | CARM1 4372/4885PRMT6 2646/4885ROCK2 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.